LY 3475070 / Eli Lilly  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LY 3475070 / Eli Lilly
KEYNOTE A57, NCT04148937: A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

Completed
1
52
Europe, US, RoW
LY3475070, Pembrolizumab
Eli Lilly and Company, Merck Sharp & Dohme LLC
Advanced Cancer
05/21
06/22

Download Options